HRHenrik Mikael Reims

Henrik Mikael Reims

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Henrik Mikael Reims has a total of 331 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Gut microbiota-derived imidazole propionate promotes primary sclerosing cholangitis via p38 signalling

    by Antonio Molinaro, Peder Rustøen Braadland, Guido Carpino, Alba Carreras, Marios Nikolaidis, Petra Hanzely, Katharina R. Beck, Ahmad H. Ali, Lars Bossen, Anna Frank, et al.

    Primary sclerosing cholangitis (PSC) is a chronic inflammatory disease of the bile ducts that can lead to biliary cancer and end-stage liver disease. PSC is associated with inflammatory bowel disease and an altered gut microbiota. However, the molecular mechanisms underlying gut–liver interactions in PSC remain poorly characterized. Here we show that the gut microbiota-derived metabolite imidazole propionate (ImP) is a disease driver in PSC. Individuals with PSC have higher circulating ImP levels than individuals with related conditions, and high ImP levels predict reduced survival in PSC. Cholangiocytes exposed to ImP show activated mammalian target of rapamycin complex 1 (mTORC1) signalling and secrete pro-inflammatory and pro-fibrogenic factors. Chronic administration of ImP to mice induces liver inflammation and fibrosis through a p38-dependent mechanism, upstream of mTORC1. We propose that chronic exposure to ImP induces cholangiocyte injury, which alone or in concert with other factors causes clinical worsening of PSC. Therefore, targeting ImP production or signalling may represent therapeutic avenues in PSC.


  • Open Access

    Bile extracellular vesicles for early cholangiocarcinoma detection in primary sclerosing cholangitis

    by Ainhoa Lapitz, Marit M. Grimsrud, Elisa Catanzaro, Pedro M. Rodrigues, Johannes R. Hov, Mikel Azkargorta, Beatriz Val, Mette Vesterhus, Krzysztof Grzyb, Henrik Mikael Reims, et al.


  • Organ monitoring and identification of ischemic liver injury during ex situ porcine liver machine perfusion—A randomized controlled study

    by Ida H. Færden, Marte M. Bliksøen, Olav M. Liavåg, Jie Hou, Waleed M. Majeed, May-Kristin Torp, Henrik M. Reims, Espen Lindholm, Robert J. Porte, Tor Inge Tønnessen, et al.

    The global shortage of donor livers has led to an increased reliance on extended-criteria donor livers, including those from donors after circulatory death. Utilizing marginal livers necessitates distinguishing between injured but recoverable livers and those that are irreversibly damaged. Bile duct injury, prevalent in these grafts, poses significant risks, as ischemic injuries can be challenging to assess and may lead to recipient bile duct strictures and ultimately graft failure. This study aimed to identify objective measurements that enhance existing viability criteria and facilitate the diagnosis of ischemic injuries. We employed ex situ machine perfusion (MP) to monitor porcine livers subjected to standardized biliary injury (BileINJ), standardized global liver injury (GlobalINJ), and no injury (CTRL, total n=23). Using microdialysis catheters and pCO 2 sensors, we analyzed liver tissue, hilar plate, and bile duct, in addition to standard viability assessments, collecting data on 77 variables. Principal component analysis indicated distinct clustering of the GlobalINJ and partially the BileINJ group away from the CTRL group during MP. Feature extraction models highlighted microdialysate lactate, lactate/pyruvate ratio, glycerol, tissue pCO 2 , and blood gas hematocrit as critical indicators for classifying liver state. Histopathological evaluations confirmed group-specific liver and bile injuries. We identified unique metabolic patterns that differentiate ischemically injured from non-injured porcine livers and were able to distinguish liver and biliary injury. Real-time monitoring of livers using microdialysis and tissue pCO 2 during MP is feasible and clinically available. Measurements taken in the hilar plate show the ability to identify bile duct damage while not introducing measurement devices to the vulnerable bile duct itself. Our findings enable more objective and timely selection of transplantable livers and warrant further investigation in clinical studies.


  • Open Access

    A retrospective evaluation of preemptive liver transplantation for bile duct dysplasia in primary sclerosing cholangitis: Balancing risks and benefits

    by Sigurd Breder, Christina Villard, Emma Eide, Benny Wang, Lise Katrine Engesæter, Henrik Mikael Reims, Johannes Roksund Hov, Espen Melum, Lars Aabakken, Pål Dag Line, et al.


  • Open Access

    Multimodal transcriptomics identifies metallothionein as a novel pathway in primary sclerosing cholangitis

    by Brian K. Chung, Markus S. Jördens, Jonas Øgaard, Henrik Mikael Reims, Benedicte Flateland, Tom Luedde, Xiaojun Jiang, Tom H. Karlsen, Espen Melum

    Background and Aims: Primary sclerosing cholangitis (PSC) is a chronic inflammatory bile duct disorder of unknown etiology characterized by uneven peribiliary infiltration and liver fibrosis. To localize potential disease pathways to specific microanatomical liver regions, we combined spatial and single-nuclei transcriptomics (snRNA-seq) to analyze biopsies from a spectrum of PSC and disease control explants. Approach and Results: Liver specimens from 23 PSC (transplant indications: 4 recurrent cholangitis, 7 dysplasia, 12 cirrhosis) and 7 disease controls with cirrhosis (4 metabolic dysfunction–associated steatohepatitis, MASH; 3 alcohol-associated liver disease, ALD) were analyzed by spatial transcriptomics (76,664 spots) and 16 of the same explants were also assessed by snRNA-seq (12 PSC, 2 MASH, 2 ALD; 91,891 nuclei). PSC livers expressed a robust signature of metallothionein ( MT1E, MT1G , MT1H ) and acute inflammation markers ( SAA1 , SAA2 ) at the parenchyma–fibrosis interface compared to disease controls. SnRNA-seq showed that the strongest metallothionein signal originated from a subtype of APOE + hepatocytes that, by spatial transcriptomics and immunohistochemistry, were consistently localized to the edge of fibrotic lesions in PSC explants. Biliary inflammation induced by 0.1% 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) feeding in mice resulted in significant Mt1 liver expression and liver MT1G expression correlated with AST, ALT, ALP, and bilirubin levels at the time of liver transplantation. Conclusions: Combinatorial spatial and high-resolution single-nuclei transcriptomics on the largest number of PSC liver explants to date revealed metallothionein as a novel PSC pathway that could be interrogated in future studies aiming to develop effective therapeutic interventions for PSC.


  • Open Access

    Clinical and biochemical impact of vitamin B6 deficiency in primary sclerosing cholangitis before and after liver transplantation

    by Peder Rustøen Braadland, Annika Bergquist, Martin Kummen, Lars Bossen, Lise Katrine Engesæter, Henrik Mikael Reims, Ida Björk, Krzysztof Grzyb, Andreas Abildgaard, Milada Cvancarova Småstuen, et al.


  • Open Access

    Aagenaes syndrome/lymphedema cholestasis syndrome 1 is caused by a founder variant in the 5’-untranslated region of UNC45A

    by Runar Almaas, Monica Atneosen-Åsegg, Mari Eknes Ytre-Arne, Maria Melheim, Hanne Sørmo Sorte, Dana Cízková, Henrik Mikael Reims, Aleš Bezrouk, Sean Philip Harrison, Janne Strand, et al.


  • Long-term survival after liver transplantation in patients with common variable immunodeficiency

    by Ina Marie Andersen, Henrik M. Reims, Krzysztok Grzyb, Børre Fevang, Espen Melum, Pål Aukrust, Kristine Wiencke, Ingvild Nordøy, Pål-Dag Line, Silje Fjellgård Jørgensen

    An abstract is unavailable. This article is available as a PDF only.


  • Open Access

    Calprotectin Expressing Donor-Derived Macrophages Increase in Acute Gastrointestinal Graft-Versus-Host Disease

    by Anders Theodor Aasebo, Tobias Gedde-Dahl, Henrik Mikael Reims, Espen Sonderaal Baekkevold, Frode Lars Jahnsen


  • Can we ablate liver lesions close to large portal and hepatic veins with MR-guided HIFU? An experimental study in a porcine model

    by Ulrik Carling, Leonid Barkhatov, Henrik M. Reims, Tryggve Storås, Frederic Courivaud, Airazat M. Kazaryan, Per Steinar Halvorsen, Eric Dorenberg, Bjørn Edwin, Per Kristian Hol

    Objectives Invasive treatment of tumors adjacent to large hepatic vessels is a continuous clinical challenge. The primary aim of this study was to examine the feasibility of ablating liver tissue adjacent to large hepatic and portal veins with magnetic resonance imaging–guided high-intensity focused ultrasound (MRgHIFU). The secondary aim was to compare sonication data for ablations performed adjacent to hepatic veins (HV) versus portal veins (PV). Materials and methods MRgHIFU ablations were performed in six male land swine under general anesthesia. Ablation cells of either 4 or 8 mm diameter were planned in clusters (two/animal) adjacent either to HV (n = 6) or to PV (n = 6), with diameter ≥ 5 mm. Ablations were made using 200 W and 1.2 MHz. Post-procedure evaluation was made on contrast-enhanced MRI (T1w CE-MRI), histopathology, and ablation data from the HIFU system. Results A total of 153 ablations in 81 cells and 12 clusters were performed. There were visible lesions with non-perfused volumes in all animals on T1w CE-MRI images. Histopathology showed hemorrhage and necrosis in all 12 clusters, with a median shortest distance to vessel wall of 0.4 mm (range 0–2.7 mm). Edema and endothelial swelling were observed without vessel wall rupture. In 8-mm ablations (n = 125), heat sink was detected more often for HV (43%) than for PV (19%; p = 0.04). Conclusions Ablations yielding coagulative necrosis of liver tissue can be performed adjacent to large hepatic vessels while keeping the vessel walls intact. This indicates that perivascular tumor ablation in the liver is feasible using MRgHIFU. Key Points • High-intensity focused ultrasound ablation is a non-invasive treatment modality that can be used for treatment of liver tumors. • This study shows that ablations of liver tissue can be performed adjacent to large hepatic vessels in an experimental setting. • Liver tumors close to large vessels can potentially be treated using this modality.